New Collaboration to Increase Payer Reimbursements and Patient Access LITTLETON Colorado, Dec. 15, 2022 GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance…

Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health LITTLETON Colorado, August 22, 2022 16:05 ET | Source: Vivos Therapeutics, Inc (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. “We are disappointed it is taking longer than usual…

August 15, 2022 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON Colorado, Aug. 15, 2022 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it will reschedule…

Call Scheduled for Monday, August 15, 2022 at 5:00 pm ET LITTLETON Colorado, Aug. 09, 2022  Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it…

Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. LITTLETON Colorado, July, 14, 2022 (BUSINESS WIRE)–Vivos Therapeutics, Inc. (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods Administration for multiple indications to include the treatment of snoring and…

Effectively Immediately, Vivos to be Exclusive Distributor for Novel Diagnostic Equipment to Evaluate Nasal Breathing and Function in Dental Patients with Sleep and Breathing Issues LITTLETON Colorado, June, 29, 2022 (GLOBE NEWSWIRE) — — Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial…

Study Recently Presented at the SLEEP 2022 Annual Meeting LITTLETON Colorado, June, 14, 2022 GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that…

Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET HIGHLANDS RANCH Colorado, April 28, 2022 GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep…

New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues HIGHLANDS RANCH Colorado, April 26, 2022 GLOBE NEWSWIRE) —  Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients with dentofacial…